Related Experiment Video
Updated: Aug 8, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Immunomodulating drugs for chronic lymphocytic leukaemia
Asher Chanan-Khan1, Carl W Porter
1Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
The Lancet. Oncology
|June 6, 2006
Summary
Targeting the tumor microenvironment in chronic lymphocytic leukemia (CLL) offers a novel therapeutic strategy. Immunomodulating agents may overcome treatment resistance in relapsed or refractory CLL by altering the cytokine milieu and enhancing immune response.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with limited curative options, often characterized by relapse.
- Current treatments, including targeted agents and chemotherapy, improve remission rates but face challenges in relapsed or refractory disease.
- The CLL tumor clone actively modulates its microenvironment, influencing cytokine production for survival and immune evasion.
Purpose of the Study:
- To explore the potential of targeting the tumor-cell microenvironment as a novel therapeutic strategy for CLL.
- To investigate the role of immunomodulating agents in overcoming treatment resistance in CLL.
Main Methods:
- Review of current therapeutic approaches for CLL.
- Analysis of the CLL tumor microenvironment and its role in disease progression and immune escape.
- Examination of immunomodulating agents as a potential treatment class.
Main Results:
- The tumor microenvironment plays a critical role in CLL growth, survival, and immune evasion.
- Targeting the microenvironment has not been previously investigated as a CLL treatment.
- Immunomodulating agents represent a promising new class of drugs with the potential to alter cytokine expression and costimulate immune cells.
Conclusions:
- Targeting the tumor-cell microenvironment is a promising, unexplored therapeutic avenue for CLL.
- Immunomodulating agents offer a novel strategy to address relapsed or refractory CLL by modulating the immune response and cytokine milieu.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...